Silvia Foti

478 total citations
25 papers, 135 citations indexed

About

Silvia Foti is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Silvia Foti has authored 25 papers receiving a total of 135 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Silvia Foti's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Silvia Foti is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Silvia Foti collaborates with scholars based in Italy, Germany and United Kingdom. Silvia Foti's co-authors include Irene Moreno, Philip R. Debruyne, Bernard Doger, Erika Hamilton, Daniel Barrios, Matt D. Galsky, Hendrik‐Tobias Arkenau, Filippo de Braud, Zenta Tsuchihashi and Evan Y. Yu and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Investigative Ophthalmology & Visual Science.

In The Last Decade

Silvia Foti

13 papers receiving 135 citations

Peers

Silvia Foti
Markus Diefenhardt Germany
Tatiana Hadjieva Bulgaria
M Zivanovic Serbia
Enya H.W. Ong Singapore
Ornella Cantale Italy
Franck Drouet France
Hao‐Jun Xie China
M. Deberne France
Alexis Vrachimis Switzerland
Zhen‐Bin Qiu China
Markus Diefenhardt Germany
Silvia Foti
Citations per year, relative to Silvia Foti Silvia Foti (= 1×) peers Markus Diefenhardt

Countries citing papers authored by Silvia Foti

Since Specialization
Citations

This map shows the geographic impact of Silvia Foti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Foti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Foti more than expected).

Fields of papers citing papers by Silvia Foti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Foti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Foti. The network helps show where Silvia Foti may publish in the future.

Co-authorship network of co-authors of Silvia Foti

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Foti. A scholar is included among the top collaborators of Silvia Foti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Foti. Silvia Foti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Volta, Alberto Dalla, Francesca Valcamonico, Andrea Zivi, et al.. (2025). Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial. Prostate Cancer and Prostatic Diseases. 29(1). 116–123. 1 indexed citations
2.
3.
Camera, Silvia, Federico Rossari, Silvia Foti, et al.. (2025). HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions. Targeted Oncology. 20(2). 269–280.
4.
Finger, Robert P., Moritz Berger, J Koch, et al.. (2025). Multi-Wavelength Autofluorescence Characteristics and Association With Inflammation in Acute Posterior Multifocal Placoid Pigment Epitheliopathy. Investigative Ophthalmology & Visual Science. 66(11). 62–62.
5.
Foti, Silvia, Silvia Camera, Federico Rossari, et al.. (2024). Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents. Expert Opinion on Investigational Drugs. 33(8). 839–849.
6.
7.
Burgio, Valentina, Monica Ronzoni, Paolo Passoni, et al.. (2024). Induction chemotherapy plus concomitant oxaliplatin-based chemoradiotherapy for locally advanced rectal cancer: A real world experience at San Raffaele Hospital.. Journal of Clinical Oncology. 42(3_suppl). 144–144. 1 indexed citations
8.
9.
Rossari, Federico, Silvia Foti, Silvia Camera, et al.. (2024). Treatment options for advanced hepatocellular carcinoma: the potential of biologics. Expert Opinion on Biological Therapy. 24(6). 455–470. 3 indexed citations
10.
Rossari, Federico, Marianna Silletta, Silvia Foti, et al.. (2024). Intermediate hepatocellular carcinoma: new horizons and prospects for our patients. Expert Review of Gastroenterology & Hepatology. 18(10). 661–672.
11.
Vitiello, Francesco, Stefano Cereda, Silvia Foti, et al.. (2023). Immunotherapy in small bowel adenocarcinoma: a potential role?. Immunological Medicine. 47(1). 1–5. 3 indexed citations
12.
Rossari, Federico, Toshifumi Tada, Masatoshi Kudo, et al.. (2023). 185P Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study. Annals of Oncology. 34. S1547–S1547. 2 indexed citations
13.
Camera, Silvia, Nicole Liscia, Silvia Foti, et al.. (2022). Does immunotherapy change the treatment paradigm in metastatic gastric cancer?. Medical Oncology. 39(12). 224–224. 2 indexed citations
14.
Foti, Silvia, et al.. (2022). Could the association of sunitinib and stereotactic ablative radiotherapy lead to abscopal effect in metastatic renal cell carcinoma?. Journal of Clinical Images and Medical Case Reports. 3(4). 1 indexed citations
15.
Galsky, Matt D., Silvia Foti, Evan Y. Yu, et al.. (2022). Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).. Journal of Clinical Oncology. 40(6_suppl). 438–438. 73 indexed citations
16.
Foti, Silvia, Chiara Lucrezia Deantoni, M. Pasetti, et al.. (2021). PO-1401 Lung metastasis from renal cell carcinoma: SBRT alone or in association with target therapy as a potential treatment option. Radiotherapy and Oncology. 161. S1151–S1152.
17.
Tsaur, Igor, Isabel Heidegger, Roderick C.N. van den Bergh, et al.. (2020). Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel—A Real-world Data Assessment. European Urology Focus. 7(6). 1308–1315. 3 indexed citations
18.
Mori, Martina, G.M. Cattaneo, I. Dell’Oca, et al.. (2019). Skin DVHs predict cutaneous toxicity in Head and Neck Cancer patients treated with Tomotherapy. Physica Medica. 59. 133–141. 19 indexed citations
19.
Mori, Martina, I. Dell’Oca, Silvia Foti, et al.. (2019). Monitoring skin dose changes during image-guided helical tomotherapy for head and neck cancer patients. Strahlentherapie und Onkologie. 196(3). 243–251.
20.
Lazzari, Chiara, Silvia Novello, Sandro Barni, et al.. (2013). Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).. Journal of Clinical Oncology. 31(18_suppl). LBA8005–LBA8005. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Markus Diefenhardt Breakdown of academic impact, for papers by Tatiana Hadjieva Breakdown of academic impact, for papers by M Zivanovic Breakdown of academic impact, for papers by Enya H.W. Ong Breakdown of academic impact, for papers by Ornella Cantale Breakdown of academic impact, for papers by Franck Drouet Breakdown of academic impact, for papers by Hao‐Jun Xie Breakdown of academic impact, for papers by M. Deberne Breakdown of academic impact, for papers by Alexis Vrachimis Breakdown of academic impact, for papers by Zhen‐Bin Qiu
Rankless by CCL
2026